@article{a6b7eeb634c443d3abcbaccd5c16c8e2,
title = "Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease",
abstract = "Introduction: Neuroimaging biomarkers are important for early diagnosis of Alzheimer's disease, and comparing multimodality neuroimaging to autopsy data is essential. Methods: We compared the pathologic findings from a prospective autopsy cohort (n = 100) to Pittsburgh compound B PET (PiB-PET), 18F-fluorodeoxyglucose PET (FDG-PET), and MRI. Correlations between neuroimaging biomarkers and neuropathologic schemes were assessed. Results: PiB-PET showed strong correlations with Thal amyloid phase and Consortium to Establish a Registry for Alzheimer's Disease score and categorized 44% of Thal phase 1 participants as positive. FDG-PET and MRI correlated modestly with Braak tangle stage in Alzheimer's type pathology. A subset of participants with “none” or “sparse” neuritic plaque scores had elevated PiB-PET signal due to diffuse amyloid plaque. Participants with findings characterized as “suspected non-Alzheimer's pathophysiology” represented 15% of the group. Discussion: PiB-PET is associated with Alzheimer's disease, neuritic plaques, and diffuse plaques. FDG-PET and MRI have modest correlation with neuropathologic schemes. Participants with findings characterized as suspected non-Alzheimer's pathophysiology most commonly had primary age-related tauopathy.",
keywords = "Alzheimer's disease, Amyloid, Amyloid-PET, Autopsy, Braak tangle stage, CERAD, Dementia, MRI, Mild cognitive impairment, Neurodegeneration, SNAP, Tau-PET, Thal amyloid stage",
author = "Lowe, {Val J.} and Lundt, {Emily S.} and Albertson, {Sabrina M.} and Przybelski, {Scott A.} and Senjem, {Matthew L.} and Parisi, {Joseph E.} and Kejal Kantarci and Bradley Boeve and Jones, {David T.} and David Knopman and Jack, {Clifford R.} and Dickson, {Dennis W.} and Petersen, {Ronald C.} and Murray, {Melissa E.}",
note = "Funding Information: This study received grant support from R01-AG040042, R01-AG011378, R01-AG041851, P50-AG016574/P1, U01-AG006786; Mangurian Foundation ; Robert H. and Clarice Smith and Abigail vanBuren AD Research Program; the Elsie and Marvin Dekelboum Family Foundation. The authors thank the patients and their families who have participated in these prospective clinical and imaging studies, and especially for the generous donation of their brain tissue to help further their knowledge in Alzheimer's disease. The authors would like to acknowledge the continuous commitment and teamwork offered by Mark Jacobsen, Ping Fang, Ariston Librero, Virginia R. Phillips, and Monica Castanedes-Casey. The authors would like to also thank Kris Johnson for assistance in collection of neuropathologic material. Funding Information: This research was supported by NIH grants, P50 AG016574 , R01 NS89757 , R01 NS089544 , R01 DC10367 , R01-AG054449 , U01 AG006786 , R21 NS094489 , by the Robert Wood Johnson Foundation , The Elsie and Marvin Dekelboum Family Foundation , The Lefkofsky Family Foundation , the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, The GHR Foundation , Dr. Corinne Schuler , and the Mayo Foundation . Funding Information: Dr. Lowe serves as a consultant for Bayer Schering Pharma, Philips Molecular Imaging, Piramal Imaging, and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. Ms. Lundt, Ms. Albertson, Mr. Przybelski, Mr. Weigand, Mr. Senjem, Dr. Parisi, Dr. Jones, and Dr. Dickson report no conflicts of interest. Dr. Kantarci serves on the data safety monitoring board for Pfizer Inc and Jannsen Alzheimer's Immunotherapy; data safety monitoring board for Takeda Global Research & Development Center, Inc. She is funded by the NIH and Minnesota Partnership for Biotechnology and Medical Genomics. Dr. Boeve receives royalties from the publication of Behavioral Neurology of Dementia and receives research support from Cephalon, Allon Therapeutics, GE Healthcare, the NIH/NIA, and the Mangurian Foundation. Dr. Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at the University of Southern California; and receives research support from the NIH. Dr. Jack serves on a scientific advisory board for Eli Lilly & Company and on a data safety monitoring board for Roche; receives research support from the NIH/NIA and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and holds stock in Johnson & Johnson. Dr. Petersen serves on scientific advisory boards for Pfizer, Inc., Janssen Alzheimer Immunotherapy, Elan Pharmaceuticals, and GE Healthcare; receives royalties from the publication of Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH/NIA. Dr. Murray receives research support from the NIH/NIA.This study received grant support from R01-AG040042, R01-AG011378, R01-AG041851, P50-AG016574/P1, U01-AG006786; Mangurian Foundation; Robert H. and Clarice Smith and Abigail vanBuren AD Research Program; the Elsie and Marvin Dekelboum Family Foundation. The authors thank the patients and their families who have participated in these prospective clinical and imaging studies, and especially for the generous donation of their brain tissue to help further their knowledge in Alzheimer's disease. The authors would like to acknowledge the continuous commitment and teamwork offered by Mark Jacobsen, Ping Fang, Ariston Librero, Virginia R. Phillips, and Monica Castanedes-Casey. The authors would like to also thank Kris Johnson for assistance in collection of neuropathologic material. This research was supported by NIH grants, P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, R01-AG054449, U01 AG006786, R21 NS094489, by the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, The Lefkofsky Family Foundation, the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, The GHR Foundation, Dr. Corinne Schuler, and the Mayo Foundation. Publisher Copyright: {\textcopyright} 2019 the Alzheimer's Association",
year = "2019",
month = jul,
doi = "10.1016/j.jalz.2019.03.016",
language = "English (US)",
volume = "15",
pages = "927--939",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "7",
}